Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    22257673 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Lapatinib;   Drug: Trastuzumab;   Drug: Endocrine Therapy;   Drug: Paclitaxel
2 Active, not recruiting
Has Results
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
Condition: Neoplasms, Breast
Interventions: Drug: Lapatinib;   Biological: Trastuzumab;   Drug: Paclitaxel

Indicates status has not been verified in more than two years